189 related articles for article (PubMed ID: 37864031)
21. Use of proteasome inhibition in the treatment of lung cancer.
Schenkein DP
Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S89-96. PubMed ID: 15638966
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
23. Schizandrin A can inhibit non‑small cell lung cancer cell proliferation by inducing cell cycle arrest, apoptosis and autophagy.
Zhu L; Wang Y; Lv W; Wu X; Sheng H; He C; Hu J
Int J Mol Med; 2021 Dec; 48(6):. PubMed ID: 34643254
[TBL] [Abstract][Full Text] [Related]
24. Proteasome Inhibition Overcomes ALK-TKI Resistance in
Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
[TBL] [Abstract][Full Text] [Related]
25. Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Kim M; Kim S; Yim J; Keam B; Kim TM; Jeon YK; Kim DW; Heo DS
Cancer Res Treat; 2023 Oct; 55(4):1134-1143. PubMed ID: 37218137
[TBL] [Abstract][Full Text] [Related]
26. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
27. Induction of G2/M Cell Cycle Arrest via p38/p21
Pai JT; Hsu MW; Leu YL; Chang KT; Weng MS
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500594
[TBL] [Abstract][Full Text] [Related]
28. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
29. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
30. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Denlinger CE; Keller MD; Mayo MW; Broad RM; Jones DR
J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1078-86. PubMed ID: 15052205
[TBL] [Abstract][Full Text] [Related]
31. LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway.
He Y; Jiang X; Duan L; Xiong Q; Yuan Y; Liu P; Jiang L; Shen Q; Zhao S; Yang C; Chen Y
Mol Cancer; 2021 Dec; 20(1):156. PubMed ID: 34856993
[TBL] [Abstract][Full Text] [Related]
32. Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer.
Cron KR; Zhu K; Kushwaha DS; Hsieh G; Merzon D; Rameseder J; Chen CC; D'Andrea AD; Kozono D
PLoS One; 2013; 8(9):e73710. PubMed ID: 24040035
[TBL] [Abstract][Full Text] [Related]
33. Long non-coding RNA LINC01133 represses KLF2, P21 and E-cadherin transcription through binding with EZH2, LSD1 in non small cell lung cancer.
Zang C; Nie FQ; Wang Q; Sun M; Li W; He J; Zhang M; Lu KH
Oncotarget; 2016 Mar; 7(10):11696-707. PubMed ID: 26840083
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib induces cellular senescence in A549 lung cancer cells by stimulating telomere shortening.
Wang L; Yin H; Huang S; Huang S; Huang C; Zhang Z; Liu H
Hum Exp Toxicol; 2022; 41():9603271221124094. PubMed ID: 36401358
[TBL] [Abstract][Full Text] [Related]
35. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice.
Chung CT; Yeh KC; Lee CH; Chen YY; Ho PJ; Chang KY; Chen CH; Lai YK; Chen CT
Pharmacol Res; 2020 Nov; 161():105183. PubMed ID: 32896579
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
37. Integrating network pharmacology and experimental models to investigate the mechanisms of dihydroartemisinin in preventing NSCLC progression via mTOR/HIF-1α signaling.
Li Y; Xiao X; Wang H; Zhou Q; Jin Z; Zhang Y; Wang Y; Yue F; Zhou S; Yang J
Eur J Pharmacol; 2021 Oct; 909():174411. PubMed ID: 34390710
[TBL] [Abstract][Full Text] [Related]
38. 3,6,2',4',5'-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancer.
Sheng Y; Li W; Zhu F; Liu K; Chen H; Yao K; Reddy K; Lim DY; Oi N; Li H; Peng C; Ma WY; Bode AM; Dong Z; Dong Z
J Biol Chem; 2014 Oct; 289(41):28192-201. PubMed ID: 25122774
[TBL] [Abstract][Full Text] [Related]
39. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Karthik S; Sankar R; Varunkumar K; Ravikumar V
Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
[TBL] [Abstract][Full Text] [Related]
40. Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.
Vangala JR; Dudem S; Jain N; Kalivendi SV
J Biol Chem; 2014 May; 289(18):12612-22. PubMed ID: 24627483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
